{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-25-000008","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2025-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.633128+00:00","generated_at":"2026-05-26T08:28:52.738146+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Travere Q4 FILSPARI sales $49.6M; plans FSGS sNDA by end Q1 2025","bullets":["Q4 total net product sales $73.5M (FILSPARI $49.6M); FY total $226.7M (FILSPARI $132.2M).","Plans to submit sNDA for FILSPARI in FSGS around end of Q1 2025, based on Phase 3 DUPLEX and Phase 2 DUET.","FDA granted full approval for IgAN in Sept 2024; received 693 new patient start forms in Q4.","Pegtibatinase Phase 3 HARMONY restart expected in 2026 after manufacturing scale-up improvements.","Cash and marketable securities $370.7M as of Dec 31, 2024, including $134.7M from Nov stock offering."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-25-000008","json":"https://secwatch.observer/filing/0001438533-25-000008.json","markdown":"https://secwatch.observer/filing/0001438533-25-000008.md","text":"https://secwatch.observer/filing/0001438533-25-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853325000008/0001438533-25-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853325000008/tvtx-20250220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T08:28:52.738146+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}